UBS analyst Danielle Antalffy downgraded Inspire Medical (INSP) to Neutral from Buy with a price target of $89, down from $230. The firm cites elevated downside risks to near term-sales growth and EPS estimates for the downgrade. Recent physician checks suggest that the headwinds highlighted during the Q2 earnings call will likely require time and higher OpEx to resolve, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: